यूरोपीय संघ - रोमानियाई - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - neoplasme colorectale - antineoplastic agents, protein kinase inhibitors - stivarga este indicat în monoterapie pentru tratamentul pacienților adulți cu:cancer colorectal metastatic (crc), care au fost tratați anterior cu, sau nu sunt considerați candidați pentru, disponibile terapii - acestea includ chimioterapie pe bază de fluoropirimidine, un anti-vegf terapie și un anti-egfr terapie;inoperabil sau metastatic tumori stromale gastro-intestinale (gist), care a progresat sau intoleranță la tratamentul anterior cu imatinib și sunitinib;carcinom hepatocelular (hcc), care au fost anterior tratați cu sorafenib.

यूरोपीय संघ - रोमानियाई - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

यूरोपीय संघ - रोमानियाई - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumorile stromale gastro-intestinale - agenți antineoplazici - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

यूरोपीय संघ - रोमानियाई - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenți antineoplazici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

रोमानिया - रोमानियाई - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd. - cipru - sunitinibum - caps. - 12,5mg - alte antineoplazice inhibitori de protein-kinaza

रोमानिया - रोमानियाई - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd. - cipru - sunitinibum - caps. - 25mg - alte antineoplazice inhibitori de protein-kinaza

रोमानिया - रोमानियाई - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd. - cipru - sunitinibum - caps. - 37,5mg - alte antineoplazice inhibitori de protein-kinaza

रोमानिया - रोमानियाई - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd. - cipru - sunitinibum - caps. - 50mg - alte antineoplazice inhibitori de protein-kinaza

रोमानिया - रोमानियाई - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 12,5mg - alte antineoplazice inhibitori de protein-kinaza

रोमानिया - रोमानियाई - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

remedica ltd - cipru - sunitinibum - caps. - 25mg - alte antineoplazice inhibitori de protein-kinaza